Hofseth BioCare cancels subsequent offering due to private placement delay

Hofseth BioCare ASA has resolved to cancel its subsequent offering, which aimed to raise gross proceeds of up to approximately NOK 30m through the issuance of up to 16,666,666 new ordinary shares at NOK 1.80 per share. The company had previously allocated 1,215,560 offer shares for gross proceeds of approximately NOK 2.2m from this offering, as announced on November 21, 2025.

The cancellation stems from a delay in the completion of a larger private placement, which successfully placed new ordinary shares for gross proceeds of approximately NOK 158m, as announced on October 27, 2025. Hofseth BioCare is awaiting all share deposits for the private placement and its registration with the Norwegian Register of Business Enterprises.

Subscribers to the subsequent offering will have their subscription amounts refunded. However, those wishing to maintain their subscription can contact the company by 16:30 (CET) on December 18, 2025. The company expects the private placement to be completed shortly and will provide further updates.